.webp)
Partnership aims to advance innovative oxysterol therapy during rising demand for treatments for metabolic diseases.
Technomark Life Sciences and MAX BioPharma have announced a significant collaboration to develop MAX BioPharma's oxysterol drug candidate, Oxy210, aimed at addressing metabolic dysfunction-associated steatohepatitis (MASH). As a strategic lead investor, Technomark is participating in MAX BioPharma’s $13 million Series A funding round to kick-start a Phase 1a/1b first-in-human study, inviting additional industry investors to join this promising opportunity.
Farhad Parhami, President and CEO of MAX BioPharma expressed enthusiasm over the partnership emphasizing its importance in advancing the development of a "safe, effective and orally bioavailable” therapy derived from their Oxysterol Therapeutics® platform. He noted the drug’s powerful antifibrotic and anti inflammatory properties could significantly impact the management of individuals suffering from MASH and its more severe progression leading to liver scarring or cirrhosis. Parhami highlighted the significance of the collaboration with Technomark as a milestone for the drug's development.
Frank Stappenbeck, Director of Chemistry at MAX BioPharma underscored the global need for effective treatment options for MASH noting that Oxy210 can be produced cost effectively using inexpensive materials through a simple chemical synthesis. The small-molecule's stability at room temperature eliminates the need for a cold supply chain, setting it apart from peptide based GLP 1 agonists.
Dr. Scott Friedman, Professor of Medicine and Director of the Institute for Liver Research at the Icahn School of Medicine at Mount Sinai explained the potential of Oxy210 to address key disease drivers such as inflammation, fibrosis and metabolic dysfunction. If preclinical success translates to human efficacy Oxy210 may emerge as a novel disease modifying agent that can be used alone or in combination with existing metabolic therapies. Allen Hakimi, CEO and Managing Director of Technomark expressed excitement about leveraging Technomark’s extensive experience in drug development to enhance MAX BioPharma’s therapeutic programs aiming to deliver much needed solutions for patients with MASH while maximizing stakeholder value.
.webp)
.webp)
